Becky Chan is a Senior Scientist at Amgen, where she leverages her extensive experience in biotherapeutics and mass spectrometry to drive innovative drug development initiatives. With over 14 years of expertise in mass spectrometry and more than 8 years in the biotherapeutics industry, Becky plays...
Becky Chan is a Senior Scientist at Amgen, where she leverages her extensive experience in biotherapeutics and mass spectrometry to drive innovative drug development initiatives. With over 14 years of expertise in mass spectrometry and more than 8 years in the biotherapeutics industry, Becky plays a pivotal role in supporting the pre-pivotal development of cutting-edge therapeutic modalities, including bispecific T-cell engagers (BiTEs), monoclonal antibodies (mAbs), and multi-specifics. Her proficiency in protein characterization using advanced mass spectrometry techniques—such as peptide mapping, disulfide bond analysis, and hydrogen-deuterium exchange (HDX) MS—enables her to meticulously assess critical quality attributes and ensure the integrity of biotherapeutics.
In her current role, Becky is instrumental in designing and implementing robust analytical methods, including liquid chromatography (LC) and LC-MS, to evaluate control strategies and stability assessments. Her collaborative approach allows her to work seamlessly with cross-functional teams encompassing drug substance, drug product formulation, regulatory CMC, toxicology, and supply chain, ensuring that pre-investigational new drug (IND) programs are delivered with precision and efficiency. Becky's expertise in molecular biology, protein chemistry, and biotechnology, combined with her strong project management skills, positions her as a key contributor to Amgen's mission of delivering transformative therapies to patients. Through her dedication to scientific excellence and innovation, Becky continues to make significant strides in the biotherapeutics landscape, driving forward the development of next-generation treatments.
